Analyte monitoring

• US 20070149875A1
• Filed: 12/28/2005
• Published: 06/28/2007
• Est. Priority Date: 12/28/2005
• Status: Active Grant

• Current Assignee: Abbott Diabetes Care Incorporated (Abbott Laboratories)
• Original Assignee: Abbott Diabetes Care Incorporated (Abbott Laboratories)
• Inventors: Cho, Hyun, Liu, Zenghe, Ouyang, Tianmei, Feldman, Benjamin
• Granted Patent: US 8,515,518 B2
• Time in Patent Office: Days
• US Class Current: 600/347
• CPC Class Codes: A61B 5/0031 Implanted circuitry
• CPC Class Codes: A61B 5/14532 for measuring glucose, e.g. by tissue impedance measurement
• CPC Class Codes: A61B 5/14865 invasive, e.g. introduced into the body by a catheter or needle or using implanted sensors

Abstract

Devices and methods for determining the concentration of an analyte are provided. Embodiments of the subject devices include analyte monitoring systems that include an analyte sensor capable of providing clinically accurate analyte data without a substantial time delay after operably positioning the sensor in a patient. Embodiments of the subject methods include operably positioning an analyte sensor in a patient and obtaining clinically accurate analyte data without a substantial time delay after the positioning. Also provided are systems and kits for use in analyte monitoring.

Claims

1. An analyte sensor comprising an antiglycolytic agent or precursor thereof.

2. The sensor of claim 1, wherein the antiglycolytic agent is fluoride, glyceraldehydes, mannose, glucosamine, mannoheptulose, sorbose-6-phophate, trehalose-6-phosphate, or combinations thereof.

3. The sensor of claim 1, wherein the antiglycolytic agent is glyceraldehyde and the glyceraldehyde is present in an amount that ranges from about 1 microgram to about 1 milligram.

4. The sensor of claim 1, wherein the sensor comprises a membrane.

5. The sensor of claim 4, wherein the membrane comprises the antiglycolytic agent or precursor thereof.

6. The sensor of claim 4, wherein the antiglycolytic agent or precursor thereof is coated on a surface of the membrane.

7. The sensor of claim 4, wherein the antiglycolytic agent or precursor thereof is incorporated into the membrane.

8. The sensor of claim 1, wherein the antiglycolytic agent or precursor thereof comprises a time-release formulation.

9. The sensor of claim 1, wherein the sensor comprises an antiglycolytic agent precursor and the precursor is an enzyme.

10. The sensor of claim 9, wherein the enzyme is trehalose-6-phosphate synthase.

11. The sensor of claim 1, wherein the analyte sensor is a glucose sensor.

13. The device of claim 1, wherein the sensor comprises an antiglycolytic agent or precursor thereof.

14. The device of claim 1, wherein the sensor comprises a membrane and the membrane comprises the antiglycolytic agent or precursor thereof.

12. A glucose monitoring device, the device comprising:

a glucose sensor capable of providing accurate analyte levels substantially immediately following positioning in a patient.

15. A system for determining the concentration of glucose, the system comprising:

an antiglycolytic agent or precursor thereof; and

an glucose sensor.

16. The system of claim 15, wherein the sensor includes the antiglycolytic agent or precursor thereof.

17. The system of claim 15, wherein the antiglycolytic agent or precursor thereof is independent of the sensor.

18. The system of claim 17, wherein the antiglycolytic agent or precursor thereof is adapted for transdermal or parenteral administration.

19. A method for determining the concentration of an analyte, the method comprising:

contacting an antiglycolytic agent or precursor thereof to an analyte determination site;

positioning an analyte sensor at the site; and

determining the concentration of an analyte with the sensor.